Loading
Latest filing published 24 May 2023 for Infant Bacterial Therapeutics, €5,779. Read the official filing
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Robert Molander discloses dealings in 2 companies, chiefly Infant Bacterial Therapeutics and Infant Bacterial Therapeutics AB. Over a trading history stretching from 4 May 2021 to 20 May 2023, the count stands at 4 filings.
Every open-market trade on record is a purchase: 4 purchases worth €106k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Since January 2023: 1 purchase and no sales on the market.
The median purchase comes to €28k.
The record was last updated on 24 May 2023 with an open-market purchase (€5,779) in Infant Bacterial Therapeutics. The median gap between a trade and its publication by Finansinspektionen is 2 days. Under the Market Abuse Regulation, managers have three business days to notify their trades. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations